|

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

RECRUITINGSponsored by University Hospital, Toulouse
Actively Recruiting
SponsorUniversity Hospital, Toulouse
Started2023-03-30
Est. completion2025-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05732974

Summary

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient with an early stage of non small cell lung cancer
* Indication of surgical resection
* Patient able to understand and give his consent
* Patient affiliated to the health insurance

Exclusion Criteria:

* Patient with another cancer in the last 5 years
* Patient with an allergy to the contrast medium
* Patient under legal protection

Conditions3

CancerLung CancerNon-small Cell Lung Cancer Stage IIIA

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.